Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure

被引：1

作者：

Paller, Amy S. ^{[1
]}

Eichenfield, Lawrence F. ^{[2
,3
]}

Silverberg, Jonathan, I ^{[4
]}

Cork, Michael J. ^{[5
,6
]}

Bangert, Christine ^{[7
]}

Irvine, Alan D. ^{[8
]}

Weidinger, Stephan ^{[9
]}

Barbarot, Sebastien ^{[10
]}

Fan, Haiyun ^{[11
]}

Alderfer, Justine ^{[11
]}

Koppensteiner, Herwig ^{[12
]}

Chittuluru, Kanti ^{[11
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[2] Univ Calif San Diego, San Diego, CA USA

[3] Rady Childrens Hosp San Diego, San Diego, CA USA

[4] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[5] Univ Sheffield, Sheffield Dermatol Res, IICD, Sheffield, England

[6] Sheffield Childrens Hosp, Sheffield, England

[7] Med Univ Vienna, Vienna, Austria

[8] Trinity Coll Dublin, St James Hosp, Sch Med, Dublin, Ireland

[9] Univ Hosp Schleswig Holstein, Kiel, Germany

[10] Nantes Univ, Hosp Ctr, Nantes, France

[11] Pfizer Inc, Collegeville, PA USA

[12] Pfizer Corp Austria GmbH, Vienna, Austria

来源：

关键词：

abrocitinib; adolescents; moderate-to-severe atopic dermatitis; long-term safety;

D O I：

10.1093/bjd/ljad162.011

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

383

引用

页数：2